Alan, you ask a very impt question that I have been pondering for quite some time.
One answer is that it is a test as to how any candidate compares to Soliris, in its prime indication, but that is obvious. If it does not compare or is about equal, end of game for this candidate.
I may be overthinking this, but there are a lot of inflammatory kidney pathologies that could be launching points. Lupus, several other nephridites. I would venture to say most preclinical complement publications are related to kidney, but as I have delved into kidney diseases over time, this is complicated also.
Sorry that I cannot be of more help. But I was really struck by what George said in the CC. And wondering about the RNAi target.